Powering efficient studies of gene function

The Charles Perkins Centre Adeno-Associated Viruses Accelerator (CPC AAV Accelerator) initiative was established in 2025 with support from the Jennie Mackenzie Research Fund. The CPC AAV Accelerator provides researchers with expert guidance and practical support in the use of AAVs in gene therapy.

Our vision

The ability to conduct mechanistic experiments is essential for understanding the function of disease-associated genes. However, many in vivo approaches for gene manipulation remain prohibitively expensive. Adeno-Associated Viruses (AAVs) offer a cost-effective and time-efficient alternative, enabling targeted gene delivery to specific tissues and cell types. This powerful tool has become increasingly important for researchers aiming to investigate gene function with precision and scalability.

Supported by the Jennie Mackenzie Research Fund, the Charles Perkins Centre AAV Accelerator provides researchers with expert guidance and practical support in the use of AAVs, and position the Charles Perkins Centre as a leader within the field of gene therapy.

The CPC AAV Accelerator

  • improves the reproducibility of AAV-based experiments by establishing standardised operating procedures

  • provides hands-on expertise to assist researchers to design tissue-specific expression vectors

  • subsidises AAV manufacturing costs for scientists at the Charles Perkins Centre.

  • pioneers innovative experimental designs using AAVs.

Work with us

Whether you’re in the process of conducting AAV-based experiments already, or just want to find out where to begin, we’re here to help. For further information or to contact us, please visit the AAV webpage on the Charles Perkins Centre Website here


Collaboration team